Filana Therapeutics Reports Preclinical Simufilam Data, Targets Phase 2a Screening by Q1 2027

Cells-published data showed simufilam reduced elevated ATF4 by about 37% in TSC2-deficient cells and affected mitochondrial pathways. Screening for a planned Phase 2a TSC-related epilepsy study is expected to begin by Q1 2027.